Quickstart Highlights

FOXO4-DRI dosage protocols focus on this innovative senolytic peptide (also known as Proxofim) designed to selectively target and eliminate senescent “zombie” cells. As a D-retro-inverso analog of the FOXO4 protein segment, FOXO4-DRI works by disrupting the FOXO4-p53 interaction in senescent cells, freeing p53 to trigger apoptosis and clear dysfunctional cells^[1][2]. Preclinical research has demonstrated benefits including improved physical fitness, restored organ function, enhanced hormonal balance, and reduced tissue fibrosis in aged animal models^[3][4]. This educational protocol presents an intermittent subcutaneous approach using a practical dilution for accurate insulin-syringe measurements.

• Reconstitute: Add 3.0 mL bacteriostatic water → 3.33 mg/mL concentration.
• Typical dose range: 300–500 mcg once daily during dosing weeks.
• Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (36–46 °F); avoid freeze–thaw cycles.

Protocol Overview

Concise summary of the intermittent senolytic regimen.

• Goal: Selectively eliminate senescent cells to support tissue rejuvenation and restore healthy cellular function^[1][3].
• Schedule: 1 week on, 1 week off cycles; 1–3 cycles total (2–6 weeks).
• Dose Range: 300–500 mcg daily during dosing weeks.
• Reconstitution: 3.0 mL per 10 mg vial (3.33 mg/mL) for accurate unit measurements.
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Dosing Protocol

Suggested intermittent pulse dosing approach.

• Start: 300 mcg daily during first dosing week.
• Target: 400–500 mcg daily for subsequent cycles if well-tolerated.
• Frequency: Once per day (subcutaneous) during dosing weeks only.
• Cycle Structure: 7 days on → 7 days off; repeat 1–3 times.
• Timing: Any consistent time; rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality and integrity.

• Lyophilized: Store at −20 °C (−4 °F) or below; −80 °C ideal for long-term storage^[6].
• Reconstituted: Refrigerate at 2–8 °C (36–46 °F); use within 28 days with bacteriostatic water^[7].
• Allow vials to reach room temperature before opening to reduce condensation uptake.
• Protect from light; keep stopper secure to prevent moisture exposure.

Important Notes

• Practical considerations for consistency and safety.
  • Use new sterile insulin syringes for each injection; dispose in a sharps container.
  • Rotate injection sites (abdomen, thighs, upper arms) to prevent local irritation.
  • Inject slowly; wait a few seconds before withdrawing the needle.
  • Document daily dose, site rotation, and any observations to maintain consistency.
  • Discard reconstituted solution after 28 days regardless of remaining volume^[7].

How This Works

FOXO4-DRI is a cell-penetrating peptide antagonist that targets the FOXO4-p53 interaction in senescent cells^[1]. In senescent cells, FOXO4 abnormally accumulates in the nucleus and binds to p53, preventing apoptosis^[2]. FOXO4-DRI is engineered with D-amino acids (D-retro-inverso configuration) to resist degradation while mimicking the FOXO4 binding region^[8]. By displacing native FOXO4 from p53, the peptide frees p53 to relocalize to mitochondria and initiate apoptosis specifically in senescent cells, while sparing healthy cells that lack the high nuclear FOXO4-p53 complexes^[1][9]. This selective senolytic action can reduce chronic inflammation from SASP (senescence-associated secretory phenotype) factors and restore tissue homeostasis^[3].

Potential Benefits & Side Effects

Observations from preclinical animal and cell culture studies.

• Supports selective clearance of senescent cells while sparing healthy, proliferating cells^[9][10].
• Preclinical studies showed improved physical fitness, fur density, and organ function in aged mice^[3].
• Research demonstrated restored testosterone levels in aged male mice by clearing senescent Leydig cells^[4].
• Reduced fibrotic tissue damage in pulmonary fibrosis models^[11].
• Animal studies reported no overt adverse effects; body and organ weights remained unchanged^[4].
• Mild injection-site reactions (redness) may occur with subcutaneous administration.
• Note: No human clinical trials have been completed as of 2025; all data are preclinical^[2].

Lifestyle Factors

Complementary strategies for optimal outcomes.

• Maintain a balanced, nutrient-dense diet to support cellular health and recovery.
• Engage in regular physical activity to reinforce metabolic and functional adaptations.
• Prioritize quality sleep and stress management to support tissue repair processes.
• Allow adequate rest during off-weeks for senescent cell clearance and tissue remodeling.

Injection Technique

General subcutaneous guidance from clinical best-practice resources^[12].

• Clean the vial stopper and skin with alcohol; allow to dry completely.
• Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue^[12].
• Do not aspirate for subcutaneous injections; inject slowly and steadily.
• Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
• Keep subsequent injections at least 1 inch apart from previous sites in the same region.

Recommended Source

Note: Product availability and specifications subject to change. Verify current product details on supplier website.

Shop at Amino Labs

References